Cargando…

Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis

To compare the immunopathology of immune checkpoint inhibitor‐induced myasthenia gravis (ICI‐MG) and idiopathic MG, we profiled the respective AChR autoantibody pathogenic properties. Of three ICI‐MG patients with AChR autoantibodies, only one showed complement activation and modulation/blocking pot...

Descripción completa

Detalles Bibliográficos
Autores principales: Masi, Gianvito, Pham, Minh C., Karatz, Tabitha, Oh, Sangwook, Payne, Aimee S., Nowak, Richard J., Howard, James F., Guptill, Jeffrey T., Juel, Vern C., O'Connor, Kevin C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187728/
https://www.ncbi.nlm.nih.gov/pubmed/36924454
http://dx.doi.org/10.1002/acn3.51761
_version_ 1785042791315800064
author Masi, Gianvito
Pham, Minh C.
Karatz, Tabitha
Oh, Sangwook
Payne, Aimee S.
Nowak, Richard J.
Howard, James F.
Guptill, Jeffrey T.
Juel, Vern C.
O'Connor, Kevin C.
author_facet Masi, Gianvito
Pham, Minh C.
Karatz, Tabitha
Oh, Sangwook
Payne, Aimee S.
Nowak, Richard J.
Howard, James F.
Guptill, Jeffrey T.
Juel, Vern C.
O'Connor, Kevin C.
author_sort Masi, Gianvito
collection PubMed
description To compare the immunopathology of immune checkpoint inhibitor‐induced myasthenia gravis (ICI‐MG) and idiopathic MG, we profiled the respective AChR autoantibody pathogenic properties. Of three ICI‐MG patients with AChR autoantibodies, only one showed complement activation and modulation/blocking potency, resembling idiopathic MG. In contrast, AChR autoantibody‐mediated effector functions were not detected in the other two patients, questioning the role of their AChR autoantibodies as key mediators of pathology. The contrasting properties of AChR autoantibodies in these cases challenge the accuracy of serological testing in establishing definite ICI‐MG diagnoses and underscore the importance of a thorough clinical assessment when evaluating ICI‐related adverse events.
format Online
Article
Text
id pubmed-10187728
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101877282023-05-17 Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis Masi, Gianvito Pham, Minh C. Karatz, Tabitha Oh, Sangwook Payne, Aimee S. Nowak, Richard J. Howard, James F. Guptill, Jeffrey T. Juel, Vern C. O'Connor, Kevin C. Ann Clin Transl Neurol Brief Communication To compare the immunopathology of immune checkpoint inhibitor‐induced myasthenia gravis (ICI‐MG) and idiopathic MG, we profiled the respective AChR autoantibody pathogenic properties. Of three ICI‐MG patients with AChR autoantibodies, only one showed complement activation and modulation/blocking potency, resembling idiopathic MG. In contrast, AChR autoantibody‐mediated effector functions were not detected in the other two patients, questioning the role of their AChR autoantibodies as key mediators of pathology. The contrasting properties of AChR autoantibodies in these cases challenge the accuracy of serological testing in establishing definite ICI‐MG diagnoses and underscore the importance of a thorough clinical assessment when evaluating ICI‐related adverse events. John Wiley and Sons Inc. 2023-03-16 /pmc/articles/PMC10187728/ /pubmed/36924454 http://dx.doi.org/10.1002/acn3.51761 Text en © 2023 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Brief Communication
Masi, Gianvito
Pham, Minh C.
Karatz, Tabitha
Oh, Sangwook
Payne, Aimee S.
Nowak, Richard J.
Howard, James F.
Guptill, Jeffrey T.
Juel, Vern C.
O'Connor, Kevin C.
Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis
title Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis
title_full Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis
title_fullStr Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis
title_full_unstemmed Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis
title_short Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis
title_sort clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187728/
https://www.ncbi.nlm.nih.gov/pubmed/36924454
http://dx.doi.org/10.1002/acn3.51761
work_keys_str_mv AT masigianvito clinicoserologicalinsightsintopatientswithimmunecheckpointinhibitorinducedmyastheniagravis
AT phamminhc clinicoserologicalinsightsintopatientswithimmunecheckpointinhibitorinducedmyastheniagravis
AT karatztabitha clinicoserologicalinsightsintopatientswithimmunecheckpointinhibitorinducedmyastheniagravis
AT ohsangwook clinicoserologicalinsightsintopatientswithimmunecheckpointinhibitorinducedmyastheniagravis
AT payneaimees clinicoserologicalinsightsintopatientswithimmunecheckpointinhibitorinducedmyastheniagravis
AT nowakrichardj clinicoserologicalinsightsintopatientswithimmunecheckpointinhibitorinducedmyastheniagravis
AT howardjamesf clinicoserologicalinsightsintopatientswithimmunecheckpointinhibitorinducedmyastheniagravis
AT guptilljeffreyt clinicoserologicalinsightsintopatientswithimmunecheckpointinhibitorinducedmyastheniagravis
AT juelvernc clinicoserologicalinsightsintopatientswithimmunecheckpointinhibitorinducedmyastheniagravis
AT oconnorkevinc clinicoserologicalinsightsintopatientswithimmunecheckpointinhibitorinducedmyastheniagravis